Company / Depreciation & Amortization
Rapport Therapeutics, Inc. Depreciation & Amortization History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$839.0K
FY2024
5-year range
$112.0K / $839.0K
FY2023-FY2024
Trend
+649.1%
vs FY2023
Sector context
#128 of 168
Health Care
What the data says
Rapport Therapeutics, Inc.'s depreciation & amortization of $839,000 is lower than 76% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$839,000 in FY2024.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 168This company $839.0K Sector average $212.9M
▼
-99.6% below sector average
Key checks
Key Insights
- In FY2024, depreciation & amortization increased 649.1% year-over-year.
- Ranks #128 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 13.36 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $839.0K | +649.1% |
| FY2023 | $112.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026